The purpose of this research is to evaluate the feasibility of using the radiotracer [Cu64]DOTATATE to detect tumors intraoperatively (during surgery) for patients with meningioma.

[Cu64]DOTATATE is a U.S. Food and Drug Administration (FDA) approved PET (positron emission tomography) radiotracer for the imaging of tumors that have a specific marker on their surface (somatostatin receptor). It has not yet been evaluated on whether it can help assess the extent of tumor removed during surgery.

Meningiomas have high levels of somatostatin receptors on their surface while cells making up the normal brain and normal brain coverings (dura) do not. Therefore, we can use PET radiotracers targeting somatostatin receptors to better visualize meningiomas. 

Participants will undergo a PET/CT or PET/MR scan of the head with [Cu64]DOTATATE 12-24 hours prior to standard of care surgery. During surgery, the neurosurgeon will use a handheld device called a gamma probe to measure the levels of this radiotracer immediately before and after removal of the tumor. 

Following surgery, participants will undergo a second [Cu64]DOTATATE PET/CT or PET/MR scan between 6 weeks and 3 months, and then a third scan between 6 months to 12 months.